| Structural highlights
Function
CIF_PSEAB Virulence factor that impairs the host airway defenses and may play an important role in the early colonization of the lung (PubMed:18458065, PubMed:20118260, PubMed:28982736). It decreases mucociliary transport and hinders bacterial clearance from the lung, likely increasing the severity or duration of the infection (PubMed:28982736). Cif decreases the apical membrane abundance of host cystic fibrosis transmembrane conductance regulator (CFTR), which plays an important role in airway mucociliary defense, and reduces the CFTR-mediated chloride ion secretion in human airway epithelial cells and kidney cells (PubMed:17502391, PubMed:21455491). It alters the intracellular trafficking of CFTR, and redirects CFTR from recycling endosomes to the lysosomal degradative pathway (PubMed:21455491). Cif acts by enhancing the interaction of the host cell deubiquitinating enzyme USP10 with the Ras GTPase-activating protein-binding protein 1 (G3BP1), which inhibits the ability of USP10 to interact with, and deubiquitinate CFTR (PubMed:21455491). Inactivation of USP10 facilitates the lysosome-mediated degradation of the CFTR secretory chloride channel, which reduces mucociliary clearance of respiratory pathogens by human airway epithelial cells (PubMed:21455491). It reduces mucociliary transport (MCT) in vitro and the clearance of P.aeruginosa from the host in vivo (PubMed:28982736). Cif also reduces the apical membrane abundance of the host ATP-dependent translocase ABCB1 (P-glycoprotein 1, MDR1) in kidney, intestine and airway epithelial cells (PubMed:18650266). In addition, it reduces the protein abundance of the antigen peptide transporter 1 (TAP1), but not protein abundance of TAP2 (PubMed:24247241). Reducing USP10 deubiquitinating activity leads to increased ubiquitination and proteasomal degradation of TAP1, which reduces TAP-mediated transport of peptides into the endoplasmic reticulum and subsequent MHC class I-mediated viral and bacterial antigen presentation at the host cell surface (PubMed:24247241). Retrograde trafficking of Cif to the endoplasmic reticulum is required for the Cif-mediated reduction in TAP1 (PubMed:24247241). In contrast, Cif has no effect on the membrane abundance of some other ABC transporters such as ABCC1 (MRP1) and ABCC2 (MRP2) (PubMed:18650266).[1] [2] [3] [4] [5] [6] [7] Cif shows epoxide hydrolase activity (PubMed:17502391, PubMed:18458065, PubMed:20118260, PubMed:21933119, PubMed:26136396, PubMed:26752215, PubMed:27980032, PubMed:28392259). The host epithelial-derived 14,15-epoxyeicosatrienoic acid (14,15-EET) was identified as an endogenous substrate (PubMed:27980032). 14,15-EET plays a particularly critical role as a paracrine stimulus for the production by neutrophils of the proresolving lipid mediator 15-epi LXA(4), which plays a critical role in limiting neutrophil activation and tissue inflammation (PubMed:27980032). Cif hydrolyzes 14,15-EET produced in response to inflammation into its cognate diol, indirectly eliminating the production of the proresolving lipid 15-epi LXA(4) by host neutrophils, which promotes sustained airway inflammation (PubMed:27980032). The epoxide hydrolase activity of Cif is also strictly required for its effects on CFTR, suggesting the existence of an epoxide signal involved in the deubiquitination and post-endocytic recycling of CFTR (PubMed:20118260, PubMed:26136396). The active site can accommodate a range of potential physiological epoxide substrates, suggesting that Cif can target and perturb key host immune signals (PubMed:28392259). It can degrade in vitro the xenobiotic substrate epoxide epibromohydrin (EBH) to its vicinal diol, 3-bromo-1,2-propanediol (PubMed:18458065, PubMed:20118260, PubMed:21933119, PubMed:26136396, PubMed:26752215). It also acts on the epoxide hydrolase synthetic substrate (S)-NEPC in a concentration-dependent manner (PubMed:17502391). Also shows activity against cis-stilbene oxide (CSO) (PubMed:20118260). Does not exhibit haloacetate dehalogenase (HAD) or haloalkane dehalogenase (HLD) activity against standard substrates (PubMed:20118260).[8] [9] [10] [11] [12] [13] [14] [15]
References
- ↑ MacEachran DP, Ye S, Bomberger JM, Hogan DA, Swiatecka-Urban A, Stanton BA, O'Toole GA. The Pseudomonas aeruginosa secreted protein PA2934 decreases apical membrane expression of the cystic fibrosis transmembrane conductance regulator. Infect Immun. 2007 Aug;75(8):3902-12. doi: 10.1128/IAI.00338-07. Epub 2007 May , 14. PMID:17502391 doi:https://dx.doi.org/10.1128/IAI.00338-07
- ↑ MacEachran DP, Stanton BA, O'Toole GA. Cif is negatively regulated by the TetR family repressor CifR. Infect Immun. 2008 Jul;76(7):3197-206. doi: 10.1128/IAI.00305-08. Epub 2008 May , 5. PMID:18458065 doi:https://dx.doi.org/10.1128/IAI.00305-08
- ↑ Ye S, MacEachran DP, Hamilton JW, O'Toole GA, Stanton BA. Chemotoxicity of doxorubicin and surface expression of P-glycoprotein (MDR1) is regulated by the Pseudomonas aeruginosa toxin Cif. Am J Physiol Cell Physiol. 2008 Sep;295(3):C807-18. doi: , 10.1152/ajpcell.00234.2008. Epub 2008 Jul 23. PMID:18650266 doi:https://dx.doi.org/10.1152/ajpcell.00234.2008
- ↑ Bahl CD, Morisseau C, Bomberger JM, Stanton BA, Hammock BD, O'Toole GA, Madden DR. Crystal structure of the cystic fibrosis transmembrane conductance regulator inhibitory factor Cif reveals novel active-site features of an epoxide hydrolase virulence factor. J Bacteriol. 2010 Apr;192(7):1785-95. Epub 2010 Jan 29. PMID:20118260 doi:10.1128/JB.01348-09
- ↑ Bomberger JM, Ye S, Maceachran DP, Koeppen K, Barnaby RL, O'Toole GA, Stanton BA. A Pseudomonas aeruginosa toxin that hijacks the host ubiquitin proteolytic system. PLoS Pathog. 2011 Mar;7(3):e1001325. doi: 10.1371/journal.ppat.1001325. Epub 2011 , Mar 24. PMID:21455491 doi:https://dx.doi.org/10.1371/journal.ppat.1001325
- ↑ Bomberger JM, Ely KH, Bangia N, Ye S, Green KA, Green WR, Enelow RI, Stanton BA. Pseudomonas aeruginosa Cif protein enhances the ubiquitination and proteasomal degradation of the transporter associated with antigen processing (TAP) and reduces major histocompatibility complex (MHC) class I antigen presentation. J Biol Chem. 2014 Jan 3;289(1):152-62. doi: 10.1074/jbc.M113.459271. Epub 2013 , Nov 18. PMID:24247241 doi:https://dx.doi.org/10.1074/jbc.M113.459271
- ↑ Hvorecny KL, Dolben E, Moreau-Marquis S, Hampton TH, Shabaneh TB, Flitter BA, Bahl CD, Bomberger JM, Levy BD, Stanton BA, Hogan DA, Madden DR. An epoxide hydrolase secreted by Pseudomonas aeruginosa decreases mucociliary transport and hinders bacterial clearance from the lung. Am J Physiol Lung Cell Mol Physiol. 2018 Jan 1;314(1):L150-L156. doi: , 10.1152/ajplung.00383.2017. Epub 2017 Oct 5. PMID:28982736 doi:https://dx.doi.org/10.1152/ajplung.00383.2017
- ↑ MacEachran DP, Ye S, Bomberger JM, Hogan DA, Swiatecka-Urban A, Stanton BA, O'Toole GA. The Pseudomonas aeruginosa secreted protein PA2934 decreases apical membrane expression of the cystic fibrosis transmembrane conductance regulator. Infect Immun. 2007 Aug;75(8):3902-12. doi: 10.1128/IAI.00338-07. Epub 2007 May , 14. PMID:17502391 doi:https://dx.doi.org/10.1128/IAI.00338-07
- ↑ MacEachran DP, Stanton BA, O'Toole GA. Cif is negatively regulated by the TetR family repressor CifR. Infect Immun. 2008 Jul;76(7):3197-206. doi: 10.1128/IAI.00305-08. Epub 2008 May , 5. PMID:18458065 doi:https://dx.doi.org/10.1128/IAI.00305-08
- ↑ Bahl CD, Morisseau C, Bomberger JM, Stanton BA, Hammock BD, O'Toole GA, Madden DR. Crystal structure of the cystic fibrosis transmembrane conductance regulator inhibitory factor Cif reveals novel active-site features of an epoxide hydrolase virulence factor. J Bacteriol. 2010 Apr;192(7):1785-95. Epub 2010 Jan 29. PMID:20118260 doi:10.1128/JB.01348-09
- ↑ Bahl CD, Madden DR. Pseudomonas Aeruginosa Cif Defines a Distinct Class of alpha/beta Epoxide Hydrolases Utilizing a His/Tyr Ring-opening Pair. Protein Pept Lett. 2011 Sep 20. PMID:21933119
- ↑ Bahl CD, Hvorecny KL, Bomberger JM, Stanton BA, Hammock BD, Morisseau C, Madden DR. Inhibiting an epoxide hydrolase virulence factor from Pseudomonas aeruginosa protects CFTR. Angew Chem Int Ed Engl. 2015 Jul 1. doi: 10.1002/anie.201503983. PMID:26136396 doi:https://dx.doi.org/10.1002/anie.201503983
- ↑ Bahl CD, Hvorecny KL, Morisseau C, Gerber SA, Madden DR. Visualizing the Mechanism of Epoxide Hydrolysis by the Bacterial Virulence Enzyme Cif. Biochemistry. 2016 Feb 9;55(5):788-97. doi: 10.1021/acs.biochem.5b01229. Epub, 2016 Jan 22. PMID:26752215 doi:https://dx.doi.org/10.1021/acs.biochem.5b01229
- ↑ Flitter BA, Hvorecny KL, Ono E, Eddens T, Yang J, Kwak DH, Bahl CD, Hampton TH, Morisseau C, Hammock BD, Liu X, Lee JS, Kolls JK, Levy BD, Madden DR, Bomberger JM. Pseudomonas aeruginosa sabotages the generation of host proresolving lipid mediators. Proc Natl Acad Sci U S A. 2017 Jan 3;114(1):136-141. doi:, 10.1073/pnas.1610242114. Epub 2016 Dec 15. PMID:27980032 doi:https://dx.doi.org/10.1073/pnas.1610242114
- ↑ Hvorecny KL, Bahl CD, Kitamura S, Lee KSS, Hammock BD, Morisseau C, Madden DR. Active-Site Flexibility and Substrate Specificity in a Bacterial Virulence Factor: Crystallographic Snapshots of an Epoxide Hydrolase. Structure. 2017 May 2;25(5):697-707.e4. doi: 10.1016/j.str.2017.03.002. Epub 2017, Apr 6. PMID:28392259 doi:https://dx.doi.org/10.1016/j.str.2017.03.002
|